GDS Wealth Management Raises Holdings in Natera, Inc. $NTRA

GDS Wealth Management boosted its position in Natera, Inc. (NASDAQ:NTRA) by 325.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,086 shares of the medical research company’s stock after purchasing an additional 40,623 shares during the period. GDS Wealth Management’s holdings in Natera were worth $7,507,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of NTRA. Price T Rowe Associates Inc. MD grew its holdings in Natera by 134.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock valued at $1,067,327,000 after buying an additional 3,871,862 shares during the last quarter. Nuveen LLC acquired a new stake in Natera during the 1st quarter valued at $113,375,000. JPMorgan Chase & Co. grew its holdings in Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock valued at $1,041,055,000 after buying an additional 660,538 shares during the last quarter. SG Americas Securities LLC grew its holdings in Natera by 8,233.5% during the 1st quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company’s stock valued at $56,270,000 after buying an additional 393,149 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Natera by 13.7% during the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock valued at $287,908,000 after buying an additional 245,719 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Down 0.6%

Shares of Natera stock opened at $160.12 on Wednesday. Natera, Inc. has a twelve month low of $110.57 and a twelve month high of $183.00. The stock has a market capitalization of $21.98 billion, a P/E ratio of -83.83 and a beta of 1.76. The business’s fifty day moving average price is $155.02 and its 200 day moving average price is $154.43.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same quarter in the previous year, the business posted ($0.30) EPS. Natera’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 6,111 shares of Natera stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $157.10, for a total value of $960,038.10. Following the transaction, the chief executive officer owned 179,071 shares in the company, valued at approximately $28,132,054.10. This trade represents a 3.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $157.07, for a total value of $471,210.00. Following the completion of the transaction, the insider directly owned 133,205 shares in the company, valued at $20,922,509.35. This trade represents a 2.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 61,792 shares of company stock worth $9,227,972 over the last ninety days. 5.63% of the stock is owned by insiders.

Analysts Set New Price Targets

NTRA has been the topic of a number of analyst reports. Cowen reiterated a “buy” rating on shares of Natera in a report on Friday, August 8th. Morgan Stanley reiterated an “overweight” rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 target price on the stock in a report on Monday, July 28th. Royal Bank Of Canada lifted their price objective on Natera from $251.00 to $255.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $193.19.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.